UCB SA (OTCMKTS:UCBJF – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $184.00 and last traded at $184.00, with a volume of 230 shares traded. The stock had previously closed at $184.00.
UCB Stock Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company’s 50-day moving average is $179.85 and its two-hundred day moving average is $154.93.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- What is a buyback in stocks? A comprehensive guide for investors
- What a Trump Win Looks Like for the Market Now and Into 2025
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
